AI illustration · not actual product photoDetails from the source.
Source-listed AICAR (SKU AR50): 50mg*10vials. PriceList(1).pdf lists 66 per 10 vials but does not specify currency; the website displays $66 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- AR50
- Source specification
- 50mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The catalogue lists the exact label “AICAR” (SKU AR50). In scientific literature, AICAr/acadesine refers to 5-aminoimidazole-4-carboxamide ribonucleoside, a nucleoside and not a peptide. The catalogue label alone does not verify that the specific supplier vial contains acadesine/AICAr; identity remains unconfirmed.
Biological mechanism
In cells, AICAr may be converted to ZMP, an AMP-mimicking nucleotide that can activate AMP-activated protein kinase (AMPK), a regulator of cellular energy metabolism. AICAr also has AMPK-independent effects, including effects on nucleotide synthesis and metabolism, so it is not a selective AMPK probe. [1]
Research focus
Research has examined cellular energy metabolism and exercise-related signaling, cardiac ischemia/reperfusion and cardiac surgery, and blood cancers. Much of the mechanistic evidence comes from cells and animals. [1]
Potential applications in the evidence
Areas investigated in human studies include perioperative cardiac protection during coronary artery bypass surgery and acadesine in relapsed/refractory chronic lymphocytic leukemia (CLL). These are research areas, not established uses or evidence of benefit for this catalogue item. The larger RED-CABG trial did not demonstrate benefit on its primary composite outcome. [1] [2] [3]
Human evidence
Early human work included healthy-volunteer pharmacology research and cardiac-surgery trials. A 1997 pooled analysis of five randomized CABG trials reported reductions in perioperative myocardial infarction and early cardiac death, but the later, larger Phase 3 RED-CABG trial stopped after a futility analysis and found no difference in the primary composite outcome (5.1% with acadesine vs 5.0% with placebo). [1] [2] A small, open-label Phase I/II CLL study of 24 participants reported exploratory changes in disease measures; it was not designed to establish efficacy. [3] These studies do not establish identity, quality, safety, or performance of the supplier-specific vial.
Known and potential effects
Human studies reported transient or mild hyperuricemia. In the small CLL study, reported adverse effects also included transient anemia and/or thrombocytopenia, renal impairment, and clinically significant transient infusion-related hypotension. A review of earlier human studies also reports asymptomatic hypoglycemia in one study. These reports apply to the studied products and settings and do not establish a complete risk profile for the listed vial. [1] [3]
Safety and contraindications
There is no FDA-approved label identified for this catalogue item from which to verify contraindications or a complete safety profile. Published clinical findings include altered uric acid and glucose measures, low blood counts, renal impairment, and transient hypotension in specific studies. The risks for the unidentified vial cannot be inferred from those studies, and absence of a verified contraindication is not evidence of safety. [1] [3]
U.S. FDA / regulatory status
The FDA orphan-drug database lists acadesine as designated for multiple myeloma and explicitly states it is not FDA-approved for that orphan indication. [4] FDA describes Drugs@FDA as a database of FDA-approved human drugs and notes its coverage limits. [5] The Drugs@FDA search endpoint returned an automated validation page during this review, so an exhaustive search for any other acadesine/AICAR approval could not be completed. No FDA approval is established for this supplier-specific vial. Approval of an active ingredient or another specific formulation, if any, would not establish approval of this item. The supplied material does not establish that it is compounded or research-only, so neither classification is asserted.
Evidence limitations
Mechanistic evidence is substantially from in-vitro and animal research, and AMPK-independent actions complicate interpretation. Human results vary by indication; the CLL data are small and uncontrolled. No supplied or reviewed evidence establishes the exact vial identity, manufacturer, lot, formulation, quality, sterility, stability, jurisdictional status, or regulatory approval. The supplied price list states SKU AR50, specification *10vials, and price 66 per 10 vials, but gives no currency.
Supporting sources
- AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review Cells / PubMed Central (NIH) · Peer-reviewed systematic review. Supports: Chemical class and relation of literature terminology, cellular conversion and AMPK/non-AMPK mechanisms, research domains, human-study overview, and reported human adverse effects.
- Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial JAMA / PubMed (NLM) · Randomized controlled human trial. Supports: RED-CABG trial design and results; no reduction in the primary composite endpoint.
- Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia: a multicenter phase I/II study Cancer Chemotherapy and Pharmacology / Springer Nature · Peer-reviewed Phase I/II human study. Supports: Small open-label CLL study, exploratory disease measures, and reported safety findings.
- Search Orphan Drug Designations and Approvals: acadesine U.S. Food and Drug Administration · Official FDA regulatory database record. Supports: Acadesine orphan designation for multiple myeloma and explicit statement that it is not FDA-approved for that orphan indication.
- Drugs@FDA: FDA-Approved Drugs U.S. Food and Drug Administration · Official FDA approved-drug database. Supports: FDA database scope and explanation of its approved-drug information; supports the distinction between an approved drug listing and this unidentified vial.